AperçuGraphiqueProfilStatistiques clésDonnées financièresTechniqueActualités
Dérivés
TraderScreen

BASILEA N/  CH0011432447  /

SIX Swiss Exchange
15/11/2024  17:31:42 Chg. -0.700 Volume Bid17:40:00 Demandez à17:40:00 Capitalisation boursière Dividende Y. Rapport P/E
40.000CHF -1.72% 36,116
Chiffrre d'affaires: 1.44 Mio.		 39.600Bid taille: 213 40.200Ask la taille: 200 523.99 Mio.CHF - 45.98
GlobeNewswire 27/08 European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire 21/08 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 13/08 Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire 09/07 ImCheck Appoints Stephan Braun as Chief Medical Officer
GlobeNewswire 20/06 Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
GlobeNewswire 16/05 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 03/05 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire 24/04 Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire 09/04 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire 04/04 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire 11/03 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire 13/02 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire 19/01 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire 15/01 Basilea announces acquisition of preclinical antibiotics program from Spexis
GlobeNewswire 05/01 Basilea provides portfolio status update
GlobeNewswire 11/12/2023 Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire 20/11/2023 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire 13/11/2023 Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire 31/10/2023 Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire 19/10/2023 Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire 17/10/2023 Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire 02/10/2023 Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire 28/09/2023 Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire 15/08/2023 Basilea reports strong revenue and profit growth in first half-year 2023
GlobeNewswire 08/03/2022 Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...